

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI424599

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
scPharmaceuticals Inc.	08/09/2024
RECEIVING PARTY DATA	
Company Name:	Perceptive Credit Holdings IV, LP
Street Address:	51 Astor Place, 10th Floor
City:	New York
State/Country:	NEW YORK
Postal Code:	10003
PROPERTY NUMBERS Total: 16	
Property Type	Number
Patent Number:	9884039
Patent Number:	10272064
Patent Number:	11433044
Application Number:	17817729
Patent Number:	11998555
Application Number:	18647335
Application Number:	18667326
Application Number:	18671025
Patent Number:	11497755
Patent Number:	11571434
Patent Number:	11559535
Patent Number:	12048709
Application Number:	18735876
Application Number:	18735889
Application Number:	18040171
Application Number:	18553271
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	

Phone: 2023704750
Email: ipteam@coagencyglobal.com
Correspondent Name: Joanna McCall
Address Line 1: 1025 Connecticut Ave NW, Suite 712
Address Line 2: Cogency Global Inc.
Address Line 4: Washington, DISTRICT OF COLUMBIA 20036

ATTORNEY DOCKET NUMBER:	2465605 JM
NAME OF SUBMITTER:	Andrew Hackett
SIGNATURE:	Andrew Hackett
DATE SIGNED:	08/13/2024

Total Attachments: 5

source=scPharma - Patent Security Agreement (Fully Executed)#page1.tiff
source=scPharma - Patent Security Agreement (Fully Executed)#page2.tiff
source=scPharma - Patent Security Agreement (Fully Executed)#page3.tiff
source=scPharma - Patent Security Agreement (Fully Executed)#page4.tiff
source=scPharma - Patent Security Agreement (Fully Executed)#page5.tiff

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT, dated as of August 9, 2024 (“*Patent Security Agreement*”), made by each of the signatories hereto (the “*Patent Grantors*”), is in favor of Perceptive Credit Holdings IV, LP, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “*Administrative Agent*”).

W I T N E S S E T H:

WHEREAS, the Patent Grantors are party to a Security Agreement dated as of August 9, 2024 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the “*Security Agreement*”) in favor of the Administrative Agent, pursuant to which the Patent Grantors are required to execute and deliver this Patent Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Patent Grantor has created in favor of the Administrative Agent a security interest in, and the Administrative Agent has become a secured creditor with respect to, the Patent Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Patent Grantor hereby grants to the Administrative Agent, for itself and on behalf of and for the ratable benefit of the other Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Patent Grantor or in which such Patent Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “*Patent Collateral*”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Patents of such Patent Grantor, including, without limitation, the registered and applied-for Patents of such Patent Grantor listed on **Schedule 1** attached hereto;

(b) to the extent not covered by **clause (a)**, all income, fees, royalties, damages or other payments now or hereafter due and payable with respect to any of the foregoing; and

(c) to the extent not covered by **clause (a)**, all causes of action for past, present or future infringement or other violation of any of the Patents.

The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement, and the Patent Grantors hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Patents made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Patent Grantor hereby authorizes and requests that the Commissioner of Patents record this Patent Security Agreement.


THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS PATENT SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.

This Patent Security Agreement may be executed by one or more of the parties to this Patent Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

[Remainder of This Page Intentionally Left Blank.]

IN WITNESS WHEREOF, each Patent Grantor has caused this PATENT SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first above written.

SCPHARMACEUTICALS INC., as Patent Grantor

By: 
Name: John Tucker
Title: President and Chief Executive Officer

Address: 25 Mall Road, Suite 203
Burlington, MA 01803

Accepted and Agreed:
PERCEPTIVE CREDIT HOLDINGS IV, LP, as the Administrative Agent

By: Perceptive Credit Opportunities GP, LLC

Its: General Partner

By 
Name: Sandeep Dixit
Title: Chief Credit Officer

By 
Name: Sam Chawla
Title: Portfolio Manager

Address:
Perceptive Credit Holdings IV, LP
c/o Perceptive Advisors LLC
51 Astor place, 10th floor
New York, NY 10003
Attn: Sandeep Dixit
Email: Sandeep@perceptivelife.com;
PFOCReporting@perceptivelife.com

With copies to:

Morrison & Foerster LLP
250 West 55th Street
New York, NY 10019
Attn: Mark S. Wojciechowski
Email: MWojciechowski@mofo.com
Tel.: (212) 468-8079

PATENTS**Patents and Patent Applications**

Patent	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE	9,884,039 (14/781,706)	2/6/2018 (4/3/2014)	scPharmaceuticals Inc.
	10,272,064 (15/877,865)	4/30/2019 (1/23/2018)	scPharmaceuticals Inc.
	11,433,044 (16/295,085)	9/6/2022 (3/7/2019)	scPharmaceuticals Inc.
	(17/817,729)	(8/5/2022)	scPharmaceuticals Inc.
CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAME	11,998,555 (17/426,765)	6/4/2024 (7/29/2021)	scPharmaceuticals Inc.
	(18/647,335)	(4/26/2024)	scPharmaceuticals Inc.
	(18/667,326)	(5/17/2024)	scPharmaceuticals Inc.
	(18/671,025)	(5/22/2024)	scPharmaceuticals Inc.
	11,497,755 (17/675,043)	11/15/2022 (2/18/2022)	scPharmaceuticals Inc.
	11,571,434 (17/879,041)	2/7/2023 (4/2/2022)	scPharmaceuticals Inc.
	11,559,535 (17/817,731)	1/24/2023 (8/5/2022)	scPharmaceuticals Inc.
	12,048,709 (18/150,590)	7/30/2024 (1/5/2023)	scPharmaceuticals Inc.
	(18/735,876)	(6/6/2024)	scPharmaceuticals Inc.
	(18/735,889)	(6/6/2024)	scPharmaceuticals Inc.
METHODS OF TREATMENT USING FUROSEMIDE	(18/040,171)	(2/1/2023)	scPharmaceuticals Inc.
	(18/553,271)	(9/29/2023)	scPharmaceuticals Inc.